Improving Outcomes from Colorectal Cancer: Diet, Lifestyle, and Chemoprevention
|
|
- Pearl Lane
- 5 years ago
- Views:
Transcription
1 Improving Outcomes from Colorectal Cancer: Diet, Lifestyle, and Chemoprevention Kimmie Ng, MD, MPH Director of Clinical Research Director, GI Biobank and Biospecimen Research Gastrointestinal Cancer Center Dana-Farber Cancer Institute Harvard Medical School Boston, MA 2018 Master Class Course
2 Disclosure Disclosure I have nothing to disclose. Off Label/Investigational Discussion In accordance with Annenberg Center policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations.
3 Audience Response Question #1 Observational studies suggest that diet and lifestyle modification can reduce the risk of developing colorectal cancer by: (A) 10% (B) 25% (C) 40% (D) 55% (E) 70%
4 Audience Response Question #2 Observational studies suggest that stage III colon cancer patients who comply with American Cancer Society Nutrition and Physical Activity Guidelines improve their disease-free survival by: (A) No improvement in disease-free survival (B) 30% (C) 50% (D) 70% (E) 90%
5
6
7 AJCC Stage and Five Year Survival Edge SB, et al. AJCC Cancer Staging Manual; 2010.
8 Doc, What should I eat? Should I exercise? What else can I do?
9 Colonoscopy: Effective But With Limits No screening Colonoscopy screening Incident CRC ( ) Distal colorectum ( ) Proximal colon ( ) Death from CRC ( ) Distal colorectum ( ) Proximal colon ( ) Nishihara R, et al. N Engl J Med 2013; 369(12): 1095.
10 Diet and Colorectal Cancer Risk The relationship between diet and cancer development has been a topic of great interest for over a century A recent search for diet and cancer in the PubMed database produced 44,240 citations (3/22/18) Geographic variation in colorectal cancer incidence Highest in Western countries 40-fold difference between U.S. and Africa Emigration studies: Migrants from low- to highincidence areas assume the incidence of the host country within one generation Many studies report conflicting results
11 Ongoing Prospective Cohort Studies Nurses Health Study (N = 121,700) OC s Smoking Weight/Ht Med. Hist. Diet Diet Diet Diet Diet Diet Diet Diet Blood samples Health Professionals Follow-Up Study (N = 52,000) Diet Diet Diet Diet Diet Diet Blood samples
12 Red Meat Intake and Risk of Colon Cancer in Women Relative Risk for Colorectal Cancer [ ] 1.50 [ ] 1.84 [ ] 2.49 [ ] P trend = 0.01 <1/month 1-4/month 2-4/week 5-6/week Servings of Beef, Pork, or Lamb >1/day Willett WC, et al. N Engl J Med 1990; 323:
13 Physical Activity and Risk of Colon Cancer Kyu HH, et al. BMJ 2016; 354: i3857.
14 Aspirin and Colorectal Cancer: Weight of the Evidence > 100 Case control and cohort studies 5 RCTs of aspirin for adenoma recurrence WHS RCT of aspirin for CV and cancer prevention CAPP2 RCT of aspirin in Lynch Syndrome > 50 CV prevention RCTs of aspirin linked with cancer outcomes
15 Aspirin and Adenoma Trials TRIAL Baron, NEJM 2003 Sandler, NEJM 2003 Benamouzig, Gastro 2003 Logan, Gastro 2008 Ishikawa, Gut 2014 NO. PATIENTS 1121 prior adenoma 635 prior CRC 272 prior adenoma 945 prior adenoma 311 prior adenoma DURATION 3 years DOSE 81 mg 325 mg RELATIVE RISK 0.83 ( ) 0.96 ( ) 3 years 325 mg 0.65 ( ) 1 year 160 mg 300 mg 0.85 ( ) 0.61 ( ) 3 years 300mg 0.79 ( ) 2 years 100 mg 0.60 ( )
16 COX-2 Inhibitors and Adenoma Trials APC TRIAL (Bertagnolli, 2006) NO. PATIENTS 2,035 Celecoxib AGENT DOSE RELATIVE RISK 200 mg BID 400 mg BID 0.67 ( ) 0.55 ( ) Arber, ,561 Celecoxib 400 mg QD 0.64 ( ) Baron, Rofecoxib 25 mg 0.76 ( )
17 More Seems To Be Better Multivariate Relative Risk for Colorectal Cancer P trend = Subjects using >14 tablets of aspirin per week had a 54% lower risk of developing colorectal cancer >14 Number of Aspirin Tablets Per Week Chan, AT, et al. N Engl J Med 2007; 356:
18 Longer Seems To Be Better Multivariate Relative Risk for Colorectal Cancer P trend < Subjects using aspirin the longest had a 42% lower risk of developing colorectal cancer >20 Years of Regular Aspirin Use Chan, AT, et al. N Engl J Med 2007; 356:
19 British Doctors Trial & UK-TIA Trial (n=7,588): Pooled Analysis Pooled HR 0.74 (95% CI, ) No aspirin Aspirin 300-1,200 mg/day Flossman E, et al. Lancet 2007; 369:
20 Aspirin Reduces Colorectal Cancer in Lynch Syndrome: CaPP2 Trial Participants completing 2 years of tx: HR 0.41 (95% CI ); P=0.02 Poisson IRR 0.37 (95% CI ); P=0.008 Poisson IRR 0.56 P=0.05 Burn J, et al. Lancet 2011; 378:
21 Aspirin for Colorectal Cancer: Making the Grade in 2016 The USPSTF recommends low-dose aspirin use for the primary prevention of cardiovascular disease and colorectal cancer Bibbins-Domingo K, et al. Ann Int Med 2016.
22 Vitamin D and Colorectal Cancer Vitamin D inhibits cell proliferation and angiogenesis, induces cell differentiation and apoptosis, and has anti-inflammatory effects Vitamin D receptor (VDR) and 1-α-hydroxylase are expressed in colorectal cancer (CRC) cells 1 Well-differentiated CRC cell lines have high VDR levels 2 Anti-proliferative effects of VitD are greatest in cell lines that express high levels of VDR 2 Animal studies: CRC-prone rats maintained on a high VitD diet develop fewer tumors and metastases than controls Treatment of APC min mice with VitD decreases tumor burden 3 Adenoma numbers and size increase in VDR-null APC min mice 4 1 Giovannucci E. Cancer Causes Control 2005; 16: Huerta S, et al. Cancer Res 2002; 62: Evans SR, et al. Clin Cancer Res 1998;4: Zheng W, et al. Int J Cancer 2011.
23 Plasma 25(OH)D and Risk of Colorectal Cancer 33% decrease in colorectal cancer with higher levels of vitamin D Ma Y, et al. J Clin Oncol 2011; 29:
24 Women s Health Initiative Trial of Vitamin D + Calcium n = 36,282 healthy post-menopausal women R A N D O M I Z A T I O N Vitamin D 400 IU/day + Calcium 1,000 mg/day Average treatment duration = 7 years Placebo Primary Endpoint: Incidence of Hip Fractures Secondary Endpoint: Incidence of Colorectal Cancer Wactawski-Wende J, et al. NEJM 2006; 354(7):
25 Secondary Endpoint: Incidence of Colorectal Cancer But. Low dose of vitamin D Short duration of supplementation Insufficient follow-up time Low adherence: Only 60% of subjects took at least 80% of required pills Wactawski-Wende J, et al. NEJM 2006; 354(7):
26 Randomized Trial of Vitamin D + Calcium n = 1,179 healthy post-menopausal women living in Nebraska R A N D O M I Z A T I O N Vitamin D 1,100 IU/day + Calcium 1,500 mg/day Calcium 1,500 mg/day Placebo Primary Endpoint: Incidence of Fractures Secondary Endpoint: Incidence of Cancer Lappe JM, et al. Am J Clin Nutr 2007; 85:
27 Secondary Endpoint: Cancer-Free Survival Ca+D Arm RR = 0.23 ( ) P <0.005 Lappe JM, et al. Am J Clin Nutr 2007; 85:
28 Follow-Up Randomized Trial of Vitamin D + Calcium n = 2,303 healthy post-menopausal women living in Nebraska R A N D O M I Z A T I O N Vitamin D 2,000 IU/day + Calcium 1,500 mg/day Placebo 4 years Primary Endpoint: Incidence of All-Type Cancer Lappe JM, et al. JAMA 2017; 317(12):
29 Incidence of Invasive and In-Situ Cancer But. Short duration of supplementation Insufficient follow-up time Use of vitamin D outside of study Mean baseline 25(OH)D was 32.7 ng/ml in placebo arm Low number of incident cancers 109 total, 8 CRC No power to assess individual cancers Lappe JM, et al. JAMA 2017; 317(12):
30 VITAL: VITamin D and OmegA-3 TriaL R A N D O M I Z A T I O N Vitamin D3 2,000 IU/d Placebo 24,000 healthy individuals across the U.S. with oversampling for African-Americans R A N D O M I Z A T I O N R A N D O M I Z A T I O N Omega-3 Fatty Acid 1 g/day Placebo Omega-3 Fatty Acid 1 g/day Placebo Primary Endpoints: Cardiovascular disease and/or Cancer
31 What Proportion of Colon Cancer Would Be Eliminated if Middle-Aged Men. Had a normal body-mass index Exercised >15 MET-hours/week Took a daily multivitamin containing folate Consumed <15 g of alcohol per day ( 1 drink per day) Did not smoke Ate 2 servings of red meat per week 71% Platz, et al. Cancer Causes Control 2000.
32 What is the role of diet and lifestyle among patients with established colon cancer?
33 CALGB 89803: Phase III Clinical Trial of Adjuvant Chemotherapy R A N D O M I Z A T I O N IFL Bolus 5-FU + leucovorin + irinotecan Roswell Park 5-FU + leucovorin NCI-sponsored adjuvant chemotherapy trial for stage III colon cancer 1,264 patients enrolled between 1999 and 2001 No significant difference found between treatment arms Saltz LB, et al. J Clin Oncol 2007; 25:
34 CALGB 89803: Diet, Lifestyle, and Medication Use Companion Study Complete 1 st questionnaire Complete 2 nd questionnaire Patients enroll on adjuvant therapy trial chemotherapy every 3 month f/u Included questions on: Diet and supplements Smoking Physical activity Medication use Other information
35 CALGB 89803: Physical Activity and Disease-Free Survival (n=832) Hazard Ratio for Recurrence or Death P trend = Subjects walking 6 hours per week had a 45% improvement in DFS < Physical Activity (MET-hours/week) >27 Meyerhardt JA, et al. J Clin Oncol 2006; 24:
36 CHALLENGE: Colon Health and Life-Long Exercise Change Trial High risk Stage II or stage III colon cancer - completed adjuvant chemotherapy within 2-6 months REGISTRATION Baseline Testing STRATIFICATION Disease stage high risk III; centre; BMI 27.5 vs. > 27.5; ECOG PS 0 vs. 1 RANDOMIZATION (n=962) ARM 1 Physical Activity Program + General Good Health Education Material (Intervention Arm) ARM 2 General Health Education Materials (Control Arm) Assessment of disease-free survival every 6 months for first 3 years and annually from years 4-10 Courneya KS, et al. Curr Oncol 2008;15(6):271-8.
37 Dietary Pattern and Colorectal Cancer Dietary patterns better reflect the real-world complexities of diet Account for interactions and synergy among dietary components Two major dietary patterns Western pattern = red meat, processed meat, refined grains, sweets and dessert, French fries, high-fat dairy products Prudent pattern = vegetables, fruit, legumes, whole grains, fish, poultry Western and prudent diet patterns predict risk of heart disease, diabetes, and colon cancer risk
38 CALGB 89803: Dietary Pattern and Disease-Free Survival (n=1,009) Hazard Ratio for Recurrence or Death Western diet Prudent diet P trend < Quintiles of Dietary Pattern 5 Meyerhardt JA, et al. JAMA 2007: 298(7):
39 Energy Balance and Colorectal Cancer Overconsumption GH Abdominal Obesity Physical Activity Insulin Resistance Competent β-cells Western Pattern Diet High Glycemic Diet Fasting Hyperinsulinemia Postprandial Hyperinsulinemia
40 5-Year Recurrence-Free Survival Non-diabetics 64% Diabetics 56% Hazard Ratio = 1.21 ( ) Meyerhardt JA, et al. J Clin Oncol 2003; 21:
41 CALGB 89803: Dietary Glycemic and Insulin Load and Disease-Free Survival Hazard Ratio for Recurrence or Death Glycemic Index: Measure of food-induced rise in plasma glucose Insulin Index: Measure of food-induced rise in plasma insulin Glycemic and Insulin Load: Total dietary intake Insulin load 1.8 Glycemic load Quintiles of Dietary Glycemic and Insulin Load Meyerhardt JA, et al. J Natl Cancer Inst Morales-Oyarvide V, et al. under review.
42 ACS Nutrition and Physical Activity Guidelines for Cancer Survivors Body-mass index <25 kg/m2 Exercise 150 minutes per week Limit red meat intake Eat 2.5 cups each of vegetables and fruits per day Choose whole grains instead of refined grains Developed point system based on ACS recommendations (0-6): 0 = poor compliance; 6 = best compliance Van Blarigan E, et al. JAMA Oncol 2018; in press.
43 CALGB 89803: ACS Score and Disease-Free Survival Hazard Ratio for Recurrence or Death P trend = Subjects with the highest compliance with ACS guidelines have a 31% improvement in DFS ACS Guidelines Score Van Blarigan E, et al. JAMA Oncol 2018; in press.
44 Aspirin Reduces Colon Cancer Mortality in Cardiovascular Trials mg daily BDAT (500 mg) UK-TIA (120 mg) mg daily UK-TIA (300 mg) TPT (75 mg) SALT (75 mg) Subtotal Total ( ) Odds Ratio (95% CI) 2 P=0.002 (sig) P=0.84 (het) Rothwell PM, et al. Lancet 2011; 377:
45 Post-Diagnosis Aspirin and Colorectal Cancer Survival in NHS/HPFS n = 1,279 stage I-III colorectal cancer patients Chan AT, et al. JAMA 2009; 302:
46 CALGB 89803: Aspirin Use and Disease-Free Survival Consistent aspirin use (n=75) Non-consistent aspirin use (n=724) Adjusted HR 0.51 (95% CI, ) Ng K, et al. J Natl Cancer Inst 2015.
47 Aspirin and Risk of Gastrointestinal Bleeding 2.4 Multivariate Relative Risk P trend < Number of Aspirin Tablets Per Week Huang, et al. Am J Med 2011.
48 Can we exploit mechanism to personalize chemoprevention and treatment?
49 Aspirin: Potential Mechanisms of Anti-Cancer Activity
50 Effect of Aspirin by Intratumoral COX-2 Expression Non- Users Regular Users All incident CRCs ( ) COX-2 positive ( ) COX-2 negative ( ) CRC-Specific Mortality ( ) COX-2 positive ( ) COX-2 negative ( ) P heterogeneity Chan AT, et al. N Engl J Med 2007; 356: Chan AT, et al. JAMA 2009; 302:
51 Aspirin and Colorectal Cancer Survival by PIK3CA Mutation Status Non- Users Regular Users P interaction CRC-Specific Mortality in NHS & HPFS ( ) PIK3CA mutant ( ) PIK3CA wild-type ( ) RFS in VICTOR ( ) PIK3CA mutant ( ) PIK3CA wild-type ( ) Liao X, et al. N Engl J Med 2012; 367: Domingo E, et al. J Clin Oncol 2013; 31:
52 CALGB/SWOG 80702: Phase III Trial of Adjuvant Therapy Resected Stage III Colon Cancer N = 2,500 R A N D O M I Z E 6 treatments of mfolfox6 12 treatments of mfolfox6 R A N D O M I Z E Celecoxib 400 mg daily Placebo Celecoxib 400 mg daily Placebo Celecoxib starts concurrently with FOLFOX and continues for 3 years
53 Plasma 25(OH)D and Colorectal Cancer Survival in NHS/HPFS Hazard Ratio for Death P trend = Subjects with the highest levels of vitamin D have a 48% improvement in survival < Plasma 25(OH)D (ng/ml) 33.1 Adjusted for age, gender, stage, grade, site, year of diagnosis, season of blood draw, BMI, and post-diagnosis physical activity) Ng K, et al. J Clin Oncol 2008; 26(18):
54 CALGB/SWOG 80405: Original Design mcrc 1st-line Strata: FOLFOX/FOLFIRI Prior adjuvant chemo Prior XRT FOLFIRI or FOLFOX MD choice Chemo + Cetuximab Chemo + Bevacizumab Chemo + Bevacizumab and Cetuximab n = Endpoint: Overall Survival Presented by: Kimmie Ng, MD, MPH
55 80405: Higher 25(OH)D Associated with Improved Survival 1.0 Quintile mos (months) 95% CI Overall Survival Probability Log rank P = 0.01 Adjusted HR 0.65 (95% CI, ) Median 25(OH)D 17.2 ng/ml n = 1,043 No. at Risk Quintiles 1 & 2 Quintiles 3 & 4 Quintile Time (years) Ng K, et al. J Clin Oncol 2015; 33 (suppl): abstract 3503.
56 80405: Higher 25(OH)D Associated with Improved PFS 1.0 Quintile mpfs (months) 95% CI Progression-Free Survival Probability Adjusted HR 0.79 (95% CI, ) Log rank P = 0.02 No. at Risk Quintiles 1 & 2 Quintiles 3 & 4 Quintile Time (Years) Ng K, et al. J Clin Oncol 2015; 33 (suppl): abstract 3503.
57 SUNSHINE: Randomized Phase II Trial Previously Untreated Metastatic CRC n=139 April 2012 November 2016 Ng K, et al. ASCO R A N D O M I Z A T I O N 1:1 FOLFOX-bevacizumab + Vitamin D3 8,000 IU/day x 2 weeks (loading dose), followed by Vitamin D3 4,000 IU/day (maintenance dose) FOLFOX-bevacizumab + Vitamin D3 400 IU/day Primary Endpoint PFS Secondary Endpoints OS RR Toxicity Plasma 25(OH)D Data lock April 25, 2017 Presented by: Kimmie Ng, MD, MPH
58 High-Dose Vitamin D Resulted in Improved PFS Arm Median PFS (months) % CI Unadjusted HR 0.69 (95% CI, ) Adjusted HR 0.67 (95% CI, ) Log rank P = 0.04 Ng K, et al. ASCO Presented by: Kimmie Ng, MD, MPH
59 Randomized Trial of Preoperative Vitamin D: Determining Transcriptional Targets Co-investigators: Surgical oncology: Thomas Clancy, MD Colorectal surgery: Ronald Bleday, MD; Joel Goldberg, MD Pathology: Jason Hornick, MD, PhD
60 Colorectal Cancer: Reducing Incidence and Mortality Decrease Risk of Developing CRC: BMI 25 mg/k2 Physical activity 15 METhours/week Alcohol <15 g/day Don t smoke Red meat 2 servings/week Consider aspirin Improve CRC Patient Survival BMI 25 mg/k2 Physical activity 15 METhours/week Avoid high glycemic and insulin load diet Avoid excessive Western diet Vitamin D 30 ng/ml Consider aspirin
Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology
Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology Charles S. Fuchs, MD, MPH Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital New
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationChemoprevention of Colorectal Cancer: Where We Stand
Chemoprevention of Colorectal Cancer: Where We Stand Andrew T. Chan, MD, MPH Division of Gastroenterology Massachusetts General Hospital 2 nd World Congress on Controversies in Gastroenterology Xi an,
More informationPersonalized Aspirin Therapy
Personalized Aspirin Therapy Nadir Arber, MD, MSc, MHA Head - Integrated Cancer Prevention Center Tel Aviv Medical Centre and Tel Aviv University Heidelberg 2014 CRC is Preventable Early detection Chemoprevention
More informationObservational Studies vs. Randomized Controlled Trials
Observational Studies vs. Randomized Controlled Trials Edward Giovannucci, MD, ScD Harvard School of Public Health Harvard Medical School Boston MA 02115 (1)The relevance of observational data as compared
More informationThe Role of Observational Studies. Edward Giovannucci, MD, ScD Departments of Nutrition and Epidemiology
The Role of Observational Studies Edward Giovannucci, MD, ScD Departments of Nutrition and Epidemiology Disclosure Information As required, I would like to report that I have no financial relationships
More informationNutrition and gastrointestinal cancer: An update of the epidemiological evidence
Nutrition and gastrointestinal cancer: An update of the epidemiological evidence Krasimira Aleksandrova, PhD MPH Nutrition, Immunity and Metabolsim Start-up Lab Department of Epidemiology German Institute
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationPrecision Chemoprevention with Aspirin
Precision Chemoprevention with Aspirin Andrew T. Chan, MD, MPH Clinical and Translational Epidemiology Unit Division of Gastroenterology Massachusetts General Hospital February 3-5, 2016 Lansdowne Resort,
More informationIs aspirin ready for colorectal cancer chemoprevention and adjuvant therapy?
Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy? Robert Benamouzig Service de Gastroentérologie Hôpital Avicenne Bobigny, France Aspirin and Colorectal carcinogenesis Aspirin
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationIs There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?
Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:
More informationMEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015
Supported by an Independent Educa1onal Grant from MEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015 BY DR. GUILLEM ARGILES, BARCELONA, SPAIN Cancers of the Lower GI Tract RAISE: A RANDOMIZED, DOUBLE-BLIND,
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationDeveloping your Integrative Self-Care Plan
Developing your Integrative Self-Care Plan Erin Sweet ND, MPH, FABNO Assistant Research Scientist Bastyr University [PRESENTER PHOTO] Naturopathic Oncology Red Cedar Wellness Center & Orion Center for
More informationBeyond Standard Therapy for Colorectal Cancer: Role of Energy Balance in Treatment of Survivors
Beyond Standard Therapy for Colorectal Cancer: Role of Energy Balance in Treatment of Survivors Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationPrimary and Secondary Prevention of Diverticular Disease
Primary and Secondary Prevention of Diverticular Disease Walid.H. Aldoori Wyeth Consumer Healthcare Inc. CANADA Falk Symposium Diverticular Disease: Emerging Evidence in a Common Condition Munich, June
More informationLifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival
Lifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival Melinda L. Irwin, PhD, MPH Associate Professor of Epidemiology Yale School of Medicine
More informationProgress towards an individualized approach to therapy: colorectal cancer
Progress towards an individualized approach to therapy: colorectal cancer Alan P. Venook, M.D. University of California, SF GIST: PET change after 4 weeks imatinib Multiple liver and upper abdominal 18
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationAspirin and Cancer Recent Developments
Recent Developments ICPV Brighton Conference 7 th September 2012 Alistair Ring Brighton and Sussex Medical School Bowel cancer death risks slashed by taking an aspirin a day. The Mirror 25 th April 2012.
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationDiet and Cancer in a U.S. cohort Containing many Vegetarians. Synnove F. Knutsen, MD, PhD Loma Linda University, Loma Linda, CA
Diet and Cancer in a U.S. cohort Containing many Vegetarians. Synnove F. Knutsen, MD, PhD Loma Linda University, Loma Linda, CA Cohort Profile: Adventist Health Study-2 - Prospective cohort study - 96,001
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
information aligned with the expected toxicity profile of panitumumab, which is well-known as panitumumab is already used as a third-line therapy for patients with mcrc. perc also noted QoL did not deteriorate
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationDr. Iain Tan. Senior Consultant GI Medical Oncologist National Cancer Centre Singapore
ESMO-ASIA 2017 Preceptorship (GI cancers) Session: Metastatic colorectal cancer, liver limited metastases Topic: Unresectable or borderline resectable : chemotherapy +/- targeted agents Dr. Iain Tan Senior
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationDietary intake and the risk of type 2 diabetes in Korea
2018 International Congress of Diabetes and Metabolism Dietary intake and the risk of type 2 diabetes in Korea Major of Food Science & Nutrition The Catholic University of Korea YoonJu Song Contents 1
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationKRAS G13D mutation testing and anti-egfr therapy
KRAS G13D mutation testing and anti-egfr therapy KRAS G13D mutation and anti-egfr therapy Current data do not support a need to specifically identify this mutation for assessing anti-egfr eligibility in
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationNutrition and Cancer Prevention. Elisa V. Bandera, MD, PhD
Nutrition and Cancer Prevention Elisa V. Bandera, MD, PhD The Causes of Cancer in the US. Sedentary lifestyle 5% Other 12% Family history 5 % Occupation 5% Tobacco 30% Reproductive factors 3% Pollution
More informationVitamin D, skin cancer and all-cause mortality
Vitamin D, skin cancer and all-cause mortality 3rd International UV and Skin Cancer Prevention Conference - Melbourne 2015 Sara Gandini, PhD Senior staff scientist Vice-director Division of Epidemiology
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationContributions of diet to metabolic problems in survivors of childhood cancer
Contributions of diet to metabolic problems in survivors of childhood cancer Kim Robien, PhD, RD, CSO, FAND Department of Exercise and Nutrition Sciences Milken Institute School of Public Health George
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationNo conflicts of interest or disclosures
Egg and Dairy Consumption: Impact on CVD Risk No conflicts of interest or disclosures Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health Cardiovascular Disease
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationLow-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers
Low-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers Ross Prentice Fred Hutchinson Cancer Research Center and University of Washington AICR, November 5, 2009 Outline
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationK-Ras mutational status and response to EGFR inhibitors for treatment of advanced CRC. Monica Bertagnolli, MD. CRA Continuing Education, November 2008
K-Ras mutational status and response to EGFR inhibitors for treatment of advanced CRC Monica Bertagnolli, MD CRA Continuing Education, November 2008 The Ras Oncogene Kirsten and Harvey: 1964 Identification
More informationNutrition and Physical Activity Cancer Prevention Guidelines and Cancer Prevention
Nutrition and Physical Activity Cancer Prevention Guidelines and Cancer Prevention Ana Maria Lopez, MD, MPH, FACP Professor of Medicine and Pathology University of Arizona Cancer Center Medical Director,
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationThe role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature 1 4
Review Article The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature 1 4 Alina Vrieling and Ellen Kampman ABSTRACT The role of
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationBreast Cancer: Weight and Exercise. Anne McTiernan, MD, PhD. Fred Hutchinson Cancer Research Center Seattle, WA
Breast Cancer: Weight and Exercise Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA Associations of Obesity with Overall & Breast Cancer Specific Survival Survival Obese vs. Non-obese
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationThe Role of Obesity and Diabetes in Cancer JOEL RUSH MS RD CSO LD CNSC FAND UT M. D. ANDERSON CANCER CENTER HOUSTON TEXAS
The Role of Obesity and Diabetes in Cancer JOEL RUSH MS RD CSO LD CNSC FAND UT M. D. ANDERSON CANCER CENTER HOUSTON TEXAS Objectives Differentiate between modifiable cancer risk factors and non-modifiable
More informationA healthy Nordic food index
A healthy Nordic food index Anja Olsen Danish Cancer Society Research Center Health effects of the Nordic diet November 13 th 2013 Outline Why study Nordic diet? How to construct a healthy Nordic food
More informationCardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis
Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis Scott D. Solomon, MD, Janet Wittes, PhD, Ernest Hawk, MD, MPH for the Celecoxib Cross Trials
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThe Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets and colorectal cancer 1 3
The Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets and colorectal cancer 1 3 Teresa T Fung, Frank B Hu, Kana Wu, Stephanie E Chiuve, Charles S Fuchs, and Edward Giovannucci ABSTRACT
More informationCarolyn J. Crandall, MD, MS On behalf of the WHI Bone SIG
Carolyn J. Crandall, MD, MS On behalf of the WHI Bone SIG Background One half of all postmenopausal women will have an osteoporosis related fracture during their lifetimes. Background Low body weight is
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationAntiangiogenic therapy in GI cancer: current status and future directions
Riccardo Giampieri, MD, PhD Università Politecnica delle Marche Ospedali Riuniti diancona Antiangiogenic therapy in GI cancer: current status and future directions Before starting Summary - Antiangiogenesis
More informationAlcohol & Cancer: from prevention to the patient
Alcohol & Cancer: from prevention to the patient -from consistency to inconsistencies- Ellen Kampman Wageningen University Academic Medical Centre St Radboud Nijmegen 23 september 2010 Alcohol and the
More informationArresting Prostate Cancer Development. By Dr. Walker
Arresting Prostate Cancer Development By Dr. Walker Objectives The many faces of prostate cancer? Discuss the pathogenesis of prostate cancer How does lifestyle impact our risk of prostate cancer? Arresting
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationWhat s New? Dr. Barbara Melosky
Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment
More informationFOR CONSUMERS AND PATIENTS
AVAILABILITY OF VITAMIN D FOR CONSUMERS AND PATIENTS Prof. Heike A. Bischoff-Ferrari, MD, DrPH Centre on Aging and Mobility, University of Zurich Dept. of Rheumatology, University Hospital Zurich Overview
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationAdventist Health Studies & The Vegetarian Edge
Adventist Health Studies & The Vegetarian Edge The Power of Natural Remedies Workshop May 7, 2018 10:20 10:50 am Seminary, N150 Sherine Brown-Fraser, PhD, RD, CPT, Chair & Associate Professor Adventist
More informationColorectal Cancer. Mark Chapman. MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist
Colorectal Cancer Mark Chapman MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist Overview Epidemiology of colorectal cancer Adenoma carcinoma sequence Tumour diagnosis & staging Treatment
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationDOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT?
DOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT? By: Dr. Dominik Modest, Medical Department III, Hospital of the University of Munich, Germany Dr. Andrea Sartore-Bianchi, Niguarda Cancer Center,
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationNutrition and Cancer: What We Know, What We Don t Know Walter C. Willett, MD, DrPH
Nutrition and Cancer: What We Know, What We Don t Know Walter C. Willett, MD, DrPH Department of Nutrition Harvard T. H. Chan School of Public Health November 16, 2016 Breast Cancer Deaths / 100,000 pop
More informationPhysical Activity & Cancer What We Know, What We Don t Know. Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA
Physical Activity & Cancer What We Know, What We Don t Know Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA What We Know Extensive epidemiologic research on relationship between
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationContinuous update of the WCRF-AICR report on diet and cancer. Protocol: Breast Cancer. Prepared by: Imperial College Team
Continuous update of the WCRF-AICR report on diet and cancer Protocol: Breast Cancer Prepared by: Imperial College Team The current protocol for the continuous update should ensure consistency of approach
More informationPanitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd
Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationNutrition for Cancer Survivors. Gretchen Gruender MS, RD, CSO Seattle Cancer Care Alliance
Nutrition for Cancer Survivors Gretchen Gruender MS, RD, CSO Seattle Cancer Care Alliance First we eat, then we do everything else. M.F.K. Fischer On the Menu Review of research Newer studies Food as chemoprevention
More information